罕见病药物氨己烯酸片哪里可以买的到

(Vigabatrin) is a chemical. Vigabatrin is an anti-epileptic drug and is clinically used to 1. Treat epilepsy in which other anti-epileptic drugs are ineffective, especially partial seizures. 2. It can also treat infantile spasms (West syndrome, West syndrome).

On August 21, 2009, the U.S. FDA approved Sabril as a monotherapy for pediatric patients 1 month to 2 years old, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjunctive (additional) treatment for adult patients with refractory complex partial epilepsy (CPS).

Dosage and usage of vigabatrin tablets: The use of vigabatrin tablets (Vigabatrin, Vigabatrin) should be done under the guidance of an epilepsy expert or a child neurologist. Reactions after taking the medication should be reported to the doctor promptly. Vigabatrin tablets are oral medicines that can be taken once or twice a day, before or after meals. It is advisable to drink half a glass of water when taking the medicine. If your epilepsy does not improve after taking it for a sufficient period of time, you should stop taking vigabatrin tablets. At this time, vigabatrin tablets should be gradually stopped under the supervision of a doctor. Children younger than 6 years old are prone to choking when taking tablets, so please pay attention to this. Adult dosage: The maximum dosage is 2-3 grams per day. It is appropriate to start taking it at 1g a day, and then according to the reaction after taking the medicine, if the reaction is good, it can be increased by 0.5g every week. Finally, the daily dosage is reached 2-3g. The maximum daily dosage should not exceed 3g. There is no inevitable connection between dosage and efficacy.

Where can I buy the rare disease drug vigabatrin tablets?

Only available in a few countries, the vigabatrin tablets produced by France's Sanofi are 500 mg x 100 tablets and cost about $1,500 per box. Patients can consult their medical companions for detailed drug purchase information.

Recommended hot articles: /newsDetail/82728.html